Details of the Drug Combination

General Information of Drug Combination (ID: DC3NGLV)

Drug Combination Name

RG6046 Apilimod

Indication

Disease Entry	Status	REF
Lymphoid neoplasm	Investigative	[1]

Component Drugs

RG6046 DMGYWIK

Apilimod DMHIS6Z

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: Mak

Zero Interaction Potency (ZIP) Score: 20.1

Bliss Independence Score: 17.077

Loewe Additivity Score: 12.636

LHighest Single Agent (HSA) Score: 21.451

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of RG6046

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Investigative	[2]

RG6046 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Modulator	[2]
------------------------------------------------------------------------------------

Indication(s) of Apilimod

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Preclinical	[3]

Apilimod Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
HUMAN phosphatidylinositol 3-phosphate 5-kinase (PIKfyve)	TT0S3MP	FYV1_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. April 17, 2020.